A recent study from the Ludwig Institute for Cancer Research Limited, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom shows that “iASPP, a previously unidentified regulator of desmosomes, prevents arrhythmogenic right ventricular cardiomyopathy ….” This study was published in the 17 February 2015 issue of Proc Natl Acad Sci U S A by Prof Xin Lu, Dr. Notari M, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based molecular therapy for Right ventricular cardiomyopathy: Repressor-element-1-silencing transcription factor suppresses arrhythmogenic right ventricular cardiomyopathy via down regulation of its target gene. Thus, pharmacological formulations encompassing “Repressor-element-1-silencing transcription factor activators” may be used to inhibit arrhythmogenic right ventricular cardiomyopathy.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based molecular therapy for Right ventricular cardiomyopathy: Repressor-element-1-silencing transcription factor suppresses arrhythmogenic right ventricular cardiomyopathy via down regulation of its target gene, 22/February/2015, 12.10 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Amount: $ 500*
Undisclosed information: How Repressor-element-1-silencing transcription factor suppresses arrhythmogenic right ventricular cardiomyopathy
